Figure 5.
In vivo antitumour effect of intracranial n-siRNA treatment: (A) Representative T2 weighted MR images of Day 3–60 for the untreated, n-siRNAscrambled and n-siRNAFNS based NPG (3µg) injected into orthotopic rat glioma (C6). Tumour growth can be seen in untreated and n-siRNAscrambled groups by Day-10 leading to mortality around Day-20, in contrast, n-siRNAFNS treated group (A1-A6) showed no significant tumour growth till 120 days (B) Graph showing quantitative tumour volume in orthotopic glioma in different treatment groups, estimated from MRI (C) H&E of brain sections showing tumour growth in (i) untreated (ii) n-siRNAscrambled (iii) n-siRNAFNS groups.*P < .001, data are mean ± SEM.